| Autor: |
Lin, Haolong, Cheng, Jiali, Zhu, Li, Zeng, Yuhao, Dai, Zhenyu, Zhang, Yicheng, Zhu, Xiaojian, Mu, Wei |
| Předmět: |
|
| Zdroj: |
Blood Cancer Journal; 6/18/2024, Vol. 14 Issue 1, p1-5, 5p |
| Abstrakt: |
This article discusses the use of cetuximab, a monoclonal antibody, to control the side effects of anti-CD5 CAR-T cell therapy. The study found that cetuximab effectively reduced the number of CAR-T cells in the blood, leading to a decrease in adverse events. The researchers also observed skin-related side effects, which were independent of cytokine release and may be caused by the on-target, off-tumor effects of CAR-T cells. The study highlights the importance of incorporating safety features, such as a switch-off system, in CAR-T cell therapies to improve their safety profile. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink